German Capital Markets Stock News

XTRA:SRT3
XTRA:SRT3Life Sciences

Sartorius Q4 Margin Miss Shifts Focus To Earnings Quality And Mix

Sartorius (XTRA:SRT3) reported Q4 results that missed expectations, with pressure on margins. Management issued cautious guidance, highlighting a focus on margin recovery. The company plans to prioritize higher value product rollouts as part of its response. These updates signal a potential inflection point in how Sartorius balances growth, profitability, and product mix. Sartorius, a supplier of equipment and solutions for the biopharma and life sciences industry, operates within long term...
XTRA:NDA
XTRA:NDAMetals and Mining

Did Strong Q1 Results and Higher Guidance Just Shift Aurubis' (XTRA:NDA) Investment Narrative?

Aurubis AG reported past first-quarter 2025–2026 results with sales of €5,293 million and net income of €322 million, both higher than a year earlier. Building on stronger metal prices, resilient copper demand and effective hedging in copper, gold and silver, Aurubis raised its full-year earnings guidance despite minor delays at the Richmond project. We will now examine how the upgraded full-year earnings guidance shapes Aurubis’ investment narrative and future risk-reward...
DB:TNIE
DB:TNIELeisure

Assessing tonies (DB:TNIE) Valuation After New Pokemon Partnership And Product Launch

Pokemon partnership puts tonies (DB:TNIE) in focus tonies (DB:TNIE) is drawing fresh investor attention after unveiling a Pikachu inspired lightning yellow Toniebox 2 and four Pokemon figurines, planned for a global rollout from summer 2026. See our latest analysis for tonies. The Pikachu themed launch comes after a strong run in the shares, with a 90 day share price return of 38.36% and a 1 year total shareholder return of 62.24%. This suggests momentum has recently picked up from a...
XTRA:EVK
XTRA:EVKChemicals

Evonik Industries (XTRA:EVK) Margin Rebound Challenges Cautious Earnings Narratives

Evonik Industries (XTRA:EVK) closed FY 2025 with fourth quarter revenue of €3.4b and EPS of €0.15, while trailing twelve month EPS stood at €1.36 on revenue of €14.1b, giving investors a clear snapshot of the current earnings run rate. Over recent periods, revenue has moved from €3.6b in Q4 2024 to €3.4b in Q4 2025, with quarterly EPS swinging from a loss of €0.33 per share in Q4 2024 to a profit of €0.15 in Q4 2025. This frames a year that mixed a weaker top line with a visibly different...
XTRA:NVM
XTRA:NVMAuto Components

Novem Group (XTRA:NVM) Margin Dip Tests Recent Earnings Improvement Narrative

Novem Group (XTRA:NVM) has put a softer Q3 2026 on the table, with revenue of €118.8 million and a small net loss of €1 million, translating into basic EPS of €0.02 loss for the quarter. The company has seen quarterly revenue move from €124 million in Q3 2025 to €137.964 million in Q4 2025, then to €128.9 million in Q1 2026 and €125.576 million in Q2 2026, while EPS has swung between a €0.06 loss and €0.36. This sets up a story of fluctuating profitability. For investors, the key question now...
XTRA:SHL
XTRA:SHLMedical Equipment

Siemens Healthineers (XTRA:SHL) Margin Improvement Reinforces Cautious Bullish Narratives

Siemens Healthineers (XTRA:SHL) opened fiscal Q1 2026 with revenue of €5.4b and basic EPS of €0.40, setting the tone for how its profitability story is evolving after a period of steady earnings growth. Over the past year, the company has seen revenue move from €5.5b in Q1 2025 to €5.4b this quarter, while basic EPS shifted from €0.42 to €0.40, against a backdrop of 6.8% earnings growth and a net profit margin that improved from 8.8% to 9.1%. This puts the focus squarely on how sustainably it...